New Findings What is the topic of this review? The emerging condition of long COVID, its
epidemiology, pathophysiological impacts on patients of different backgrounds …

This article updates and extends a previous BMJ Practice Pointer published in August 2020
when almost no peer reviewed research or evidence based guidance on the condition was …

Infection with severe acute respiratory syndrome coronavirus 2 associates with diverse
symptoms, which can persist for months. While antiviral antibodies are protective, those …

There has been an important change in the clinical characteristics and immune profile of
Coronavirus disease 2019 (COVID‐19) patients during the pandemic thanks to the …

Post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection are debilitating, clinically heterogeneous and of unknown molecular etiology. A …

Lung-infiltrating macrophages create a marked inflammatory milieu in a subset of patients
with COVID-19 by producing a cytokine storm, which correlates with increased lethality …

COVID-19 was primarily considered a pulmonary disease with extrapulmonary
manifestations. As the pandemic spread, there has been growing evidence that the disease …

With a global tally of more than 500 million cases of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infections to date, there are growing concerns about the post …

The vaccine and drug discovery responses to COVID-19 have worked far better than could
have been imagined. Yet by the end of 2021, more than 5 million people had died, and the …

Individuals with SARS-CoV-2 infection can develop symptoms that persist well beyond the
acute phase of COVID-19 or emerge after the acute phase, lasting for weeks or months after …